A carregar...
Evaluation of effect of bevacizumab on central subfield macular thickness in the injected and contralateral (untreated) eye of patients with bilateral diabetic macular oedema
PURPOSE: Antivascular endothelial growth factor (anti-VEGFs)—bevacizumab is routinely utilised for the treatment of diabetic macular oedema (DME). We plan to evaluate the impact of bevacizumab on the central subfield macular thickness (CSMT) of the treated and untreated eye. METHODS: A sequential gr...
Na minha lista:
| Publicado no: | BMJ Open Ophthalmol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5895978/ https://ncbi.nlm.nih.gov/pubmed/29657972 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjophth-2017-000102 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|